Chronopharmacology of roflumilast: A comparative pharmacokinetic study of morning versus evening administration in healthy adults

Chronobiology International

Volumn 27, Issue 9-10, 2010, Pages 1843-1853

  Bethke, Thomas D ^a   Huennemeyer, Andreas ^b   Lahu, Gezim ^b   Lemmer, Bjrn ^c  

^a Nycomed GmbH   (Germany)

^b Nycomed GmbH   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Chronopharmacokinetics; Circadian; COPD; Human; Roflumilast

Indexed keywords

AMINOPYRIDINE DERIVATIVE; BENZAMIDE DERIVATIVE; CYCLOPROPANE DERIVATIVE; ROFLUMILAST; ROFLUMILAST N OXIDE; ROFLUMILAST N-OXIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD; CIRCADIAN RHYTHM; DRUG ADMINISTRATION; DRUG EFFECT; DRUG TOLERANCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTESTINE ABSORPTION; METHODOLOGY; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PHYSIOLOGY; SAFETY;

ADMINISTRATION, ORAL; ADULT; AMINOPYRIDINES; AREA UNDER CURVE; BENZAMIDES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CIRCADIAN RHYTHM; CYCLOPROPANES; DRUG ADMINISTRATION SCHEDULE; DRUG TOLERANCE; HUMANS; INTESTINAL ABSORPTION; SAFETY; THERAPEUTIC EQUIVALENCY;

EID: 78049282433     PISSN: 07420528     EISSN: 15256073     Source Type: Journal    
DOI: 10.3109/07420528.2010.520398     Document Type: Article

References (32)

1. Almeida L, Falcão A, Vaz-da-Silva M, Coelho R, Albino-Teixeira A, Soares-da-Silva P. (2008). Personality characteristics of volunteers in Phase 1 studies and likelihood of reporting adverse events. Int. J. Clin. Pharmacol. Ther. 46:340-348.
2. Altman LC, Munk Z, Seltzer J, Noonan N, Shingo S, Zhang J, Reiss TF. (1998). A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. Montelukast Asthma Study Group. J. Allergy Clin. Immunol. 102:50-56.
3. Beam WR, Weiner DE, Martin RJ. (1992). Timing of prednisone and alterations of airways inflammation in nocturnal asthma. Am. Rev. Respir. Dis. 146:1524-1530.
4. Bethke TD, Böhmer GM, Hermann R, Hauns B, Fux R, Mörike K, David M, Knoerzer D, Wurst W, Gleiter CH. (2007). Dose-proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor. J. Clin. Pharmacol. 47:26-36.
5. Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, Beume R. (2001). In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J. Pharmacol. Exp. Ther. 297:280-290
6. Calverley PM, Lee A, Towse L, van Noord J, Witek TJ, Kelsen S. (2003). Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax 58:855-860.
7. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ, M2-124 and M2-125 study groups. (2009). Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 374:685-694.
8. Casale R, Pasqualetti P. (1997). Cosinor analysis of circadian peak expiratory flow variability in normal subjects, passive smokers, heavy smokers, patients with chronic obstructive pulmonary disease and patients with interstitial lung disease. Respiration 64:251-256.
9. D'Urzo A, Karpel JP, Busse WW, Boulet LP, Monahan ME, Lutsky B, Staudinger H. (2005). Efficacy and safety of mometasone furoate administered once-daily in the evening in patients with persistent asthma dependent on inhaled corticosteroids. Curr. Med. Res. Opin. 21:1281-1289.
10. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, Rabe KF, M2-127 and M2-128 study groups. (2009). Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 374:695-703.
11. Faurschou P, Engel AM, Haanaes OC. (1994). Salmeterol in two different doses in the treatment of nocturnal bronchial asthma poorly controlled by other therapies. Allergy 49:827-832.
12. Goo RH, Moore JG, Greenberg E, Alazraki NP. (1987). Circadian variation in gastric emptying of meals in humans. Gastroenterology 93:515-518.
13. Hatzelmann A, Schudt C. (2001). Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J. Pharmacol. Exp. Ther. 297:267-279.
14. Hauns B, Huennemeyer A, Seiberling M, Zech R, Kuelzer R, Reuter F, Bethke D. (2003). Pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects after a single, oral dose of 500 'g roflumilast in the morning vs evening. Eur. Respir. J. 22:102s. (Abstract P716)
15. Hauns B, Hermann R, Hünnemeyer A, Herzog R, Hauschke D, Zech K, Bethke TD. (2006). Investigation of a potential food effect on the pharmacokinetics of roflumilast, an oral, oncedaily phosphodiesterase 4 inhibitor, in healthy subjects. J. Clin. Pharmacol. 46:1146-1153.
16. Hetzel MR, Clark TJH. (1980). Comparison of normal and asthmatic circadian rhythms in peak expiratory flow rate. Thorax 35:732-738.
17. Huic M, Vrhovac B, Macolic-Sarinic V, Francetic I, Bakran I, Giljanovic S. (1996). How safe are bioequivalence studies in healthy volunteers? Thérapie 51:410-413.
18. Kraft M, Hamid Q, Chrousos GP, Martin RJ, Leung DY. (2001). Decreased steroid responsiveness at night in nocturnal asthma. Is the macrophage responsible? Am. J. Respir. Crit. Care Med. 163:1219-1225.
19. Lemmer B. (1999). Chronopharmacokinetics: implications for drug treatment. J. Pharm. Pharmacol. 51:887-890.
20. Lemmer B. (2007). Chronobiology, drug-delivery, and chronotherapeutics. Adv. Drug Deliv. Rev. 59:825-827.
21. Lemmer B, Bruguerolle B. (1994). Chronopharmacokinetics. Are they clinically relevant? Clin. Pharmacokinet. 26:419-427.
22. Lemmer B, Nold G. (1991). Circadian changes in estimated hepatic blood flow in healthy subjects. Br. J. Clin. Pharmacol. 32:627-629.
23. Nisar M, Walshaw M, Earis JE, Pearson MG, Calverley PM. (1990). Assessment of reversibility of airway obstruction in patients with chronic obstructive airways disease. Thorax 45:190-194.
24. Pincus DJ, Szefler SJ, Ackerson LM, Martin RJ. (1995). Chronotherapy of asthma with inhaled steroids: the effect of dosage timing on drug efficacy. J. Allergy Clin. Immunol. 95:1172-1178.
25. Portaluppi F, Touitou Y, Smolensky MH. (2008). Ethical and methodological standards for laboratory and medical biological rhythm research. Chronobiol. Int. 25:999-1016.
26. Postma DS, Koëter GH, vd Mark TW, Reig RP, Sluiter HJ. (1985). The effects of oral slow-release terbutaline on the circadian variation in spirometry and arterial blood gas levels in patients with chronic airflow obstruction. Chest 87:653-657.
27. Postma DS, Sevette C, Martinat Y, Schlösser N, Aumann J, Kafé H. (2001). Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening. Eur. Respir. J. 17:1083-1088.
28. Rodgers A, Bateman DN, Woodhouse KW. (1988). Is diurnal variation in absorption of slow-release aminophylline in the elderly an age-related phenomenon? Eur. J. Clin. Pharmacol. 33:593-597.
29. Schuirmann DJ. (1987). A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J. Pharmacokinet. Biopharm. 15:657-680.
30. Sibille M, Deigat N, Janin A, Kirkesseli S, Durand DV. (1998). Adverse events in phase-I studies: a report in 1015 healthy volunteers. Eur. J. Clin. Pharmacol. 54:13-20.
31. Smolensky MH, Barnes PJ, Reinberg A, McGovern JP. (1986). Chronobiology and asthma. I. Day-night differences in bronchial patency and dyspnea and circadian rhythm dependencies. J. Asthma 23:321-343.
32. Smolensky MH, Lemmer B, Reinberg AE. (2007). Chronobiology and chronotherapy of allergic rhinitis and bronchial asthma. Adv. Drug Deliv. Rev. 59:852-882.